CRS-RS.5p and CRS-RS risk scores vs CRS grade by ASTCT in GO43921 + NP30179 data sets after the first dose of glofitamab in the second-line or later treatment of NHL. Triangles represent patients in the prospective part of GO43921, diamonds represent patients with NHL recruited to NP30179 between October 2021 and April 2022. Every patient from the complete analysis cohort is represented by a colored dot. In the right-hand side panel, green dots indicate patients with a low-risk classification as assessed by the CRS-RS model in the NP30179 study; red dots indicate patients that were not deemed low-risk by the CRS-RS model in the NP30179 study. In the left-hand side panel, black dots represent patients in the GO43921 study. For every patient, the ASTCT CRS grade category corresponds to the maximum ASTCT grade of all CRS events recorded in the first week after the first dose of glofitamab. NHL, non-Hodgkin lymphoma.